Assenagon Asset Management S.A. Takes $469,000 Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Assenagon Asset Management S.A. acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMCFree Report) in the 3rd quarter, Holdings Channel reports. The firm acquired 9,337 shares of the biotechnology company’s stock, valued at approximately $469,000.

Other hedge funds also recently modified their holdings of the company. Raymond James & Associates lifted its position in Blueprint Medicines by 18.6% in the first quarter. Raymond James & Associates now owns 31,565 shares of the biotechnology company’s stock worth $2,016,000 after purchasing an additional 4,945 shares during the period. US Bancorp DE lifted its position in Blueprint Medicines by 11.4% in the first quarter. US Bancorp DE now owns 7,234 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 743 shares during the period. MetLife Investment Management LLC lifted its position in Blueprint Medicines by 53.9% in the first quarter. MetLife Investment Management LLC now owns 31,782 shares of the biotechnology company’s stock worth $2,030,000 after purchasing an additional 11,131 shares during the period. Rhumbline Advisers lifted its position in Blueprint Medicines by 1.5% in the first quarter. Rhumbline Advisers now owns 63,434 shares of the biotechnology company’s stock worth $4,052,000 after purchasing an additional 924 shares during the period. Finally, BlackRock Inc. lifted its position in Blueprint Medicines by 0.9% in the first quarter. BlackRock Inc. now owns 5,383,138 shares of the biotechnology company’s stock worth $343,876,000 after purchasing an additional 46,264 shares during the period.

Blueprint Medicines Price Performance

Shares of BPMC stock opened at $74.20 on Thursday. The stock has a 50-day moving average price of $82.57 and a 200 day moving average price of $63.88. The company has a quick ratio of 4.01, a current ratio of 4.09 and a debt-to-equity ratio of 1.03. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of -8.07 and a beta of 0.61. Blueprint Medicines Co. has a 12 month low of $37.82 and a 12 month high of $94.00.

Insider Buying and Selling

In related news, insider Christopher K. Murray sold 600 shares of Blueprint Medicines stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $71.43, for a total value of $42,858.00. Following the completion of the sale, the insider now directly owns 24,495 shares in the company, valued at $1,749,677.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Christopher K. Murray sold 600 shares of Blueprint Medicines stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $71.43, for a total value of $42,858.00. Following the completion of the sale, the insider now directly owns 24,495 shares in the company, valued at $1,749,677.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 714 shares of Blueprint Medicines stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $90.00, for a total value of $64,260.00. Following the completion of the sale, the insider now owns 14,324 shares of the company’s stock, valued at $1,289,160. The disclosure for this sale can be found here. Insiders sold a total of 51,314 shares of company stock worth $3,895,268 over the last three months. 3.88% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BPMC has been the subject of several research reports. Morgan Stanley raised their target price on Blueprint Medicines from $59.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. Needham & Company LLC increased their price objective on Blueprint Medicines from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Wedbush reiterated an “outperform” rating and set a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday. Raymond James increased their price objective on Blueprint Medicines from $85.00 to $100.00 and gave the stock a “strong-buy” rating in a research note on Friday, December 22nd. Finally, JMP Securities reiterated a “market outperform” rating and set a $114.00 price objective on shares of Blueprint Medicines in a research note on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.00.

Read Our Latest Research Report on Blueprint Medicines

About Blueprint Medicines

(Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib.

See Also

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMCFree Report).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.